- Lilly, with new data, to seek FDA approval of obesity drug retatrutideThe new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.BioPharma Dive · 5d ago↗ source
- Scancell to go public after winning reverse merger bid for troubled NeuphoriaScancell and Neuphoria have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders after the biotech ended it…Fierce Biotech · 6d ago↗ source
- Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearEli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…